J Korean Ophthalmol Soc.  2010 Oct;51(10):1299-1304.

Effect of Intravenous Methylprednisolone on Idiopathic Orbital Inflammation

• Chung SA
• Yoon JS
• Lee SY

Abstract

PURPOSE
To evaluate the efficacy of intravenous methylprednisolone pulse therapy in patients with idiopathic orbital inflammation.
METHODS
Fifty-two patients who received three-day pulse methylprednisolone for acute severe swelling, loss of visual acuity, limitation of eye movement, diplopia, or pain were included in the present study. The lesions were divided into five subtypes using computed tomography or magnetic resonance imaging; anterior, lacrimal, myositic, diffuse and apical. A case diagnosed as sclerotic type was excluded. The response rate, recurrence rate and cure rate were assessed.
RESULTS
The total response rate to intravenous methylprednisolone from all groups was 84.6%, with 100% in the anterior subtype and 71.4% in the diffuse subtype. During the mean follow-up period of 10.5 months, 15.9% of patients experienced a recurrence after a mean of 5.7 months. Overall, the cure rate was 71.2%. Recurrence was more common in the younger patients, and three of the seven patients with recurrence had myositic inflammation.
CONCLUSIONS
Intravenous methylprednisolone was effective in patients with severe idiopathic orbital inflammation. However, combining other treatment modalities in patients with diffuse or myositic subtypes and in younger patients who show relatively low response or high recurrence is recommended.

Keyword

Idiopathic orbital inflammation; Methylprednisolone; Pseudotumor; Steroid

MeSH Terms

Diplopia
Eye Movements
Follow-Up Studies
Humans
Inflammation
Magnetic Resonance Spectroscopy
Methylprednisolone
Orbit
Recurrence
Visual Acuity
Methylprednisolone

Figure

• 

  Figure 1. Comparison of ocular symptoms and signs of idiopathic orbtal inflammation before and after intravenous methylprednisolone pulse therapy. Pre = pre-intravenous corticosteroid pulse therapy, Post = immediate after intravenous corticosteroid pulse therapy.

Reference

References

1. Jacobs D, Galetta S. Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol. 2002; 13:347–51.

2. Henderson JW. Orbital tumors. 2nd ed.New York: Thieme-Stratton;1980. p. 512–45.

3. Günalp I, Gündüz K, Yazar Z. Idiopathic orbital inflammatory disease. Acta Ophthalmol Scand. 1996; 74:191–3.

4. Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L. What is orbital Pseudotumor? Surv Ophthalmol. 1996; 41:66–78.

5. Leone CR Jr, Lloyd WC 3rd. Treatment protocol for orbital inflammatory disease. Ophthalmology. 1985; 92:1325–31.

6. Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology. 1997; 104:402–8.

7. Mombaerts I, Schlingemann RO, Goldschmeding R, Koornneff L. Are systemic corticosteroids useful in the management of orbital pseudotumor? Ophthalmology. 1996; 103:521–8.

8. Wirostko BM, Wirostko E, Wirostko RF. Orbital pseudotumors treated with systemic corticosteroids. Ophthalmology. 1996; 103:1519–20.

9. Yan J, Wu Z, Li Y. The differentiation of idiopathic inflammatory pseudotumor from lymphoid tumors of orbit: analysis of 319 cases. Orbit. 2004; 23:245–54.

10. Yan J, Qiu H, Wu Z, Li Y. Idiopathic orbital inflammatory pseudotumor in Chinese children. Orbit. 2006; 25:1–4.

11. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003; 121:491–9.

12. Park SJ, Jung SS, Lee DG, Jang JW. Pseudotumor: distribution, clinical features, treatment outcomes. J Korean Ophthalmol Soc. 2008; 49:1379–86.

13. Lee H, Kim SJ, Lee SY. Classification and treatment efficacy of orbital pseudotumor. J Korean Ophthalmol Soc. 2001; 42:1647–54.

14. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci. 2005; 42:71–104.

15. Woltman AM, Massacrier C, de Fijter JW, et al. Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development. J Immunol. 2002; 168:6181–8.

16. Suda T, Chida K, Matsuda H, et al. High-dose intravenous glucocorticoid therapy abrogates circulating dendritic cells. J Allergy Clin Immunol. 2003; 112:1237–9.

17. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005; 90:5234–40.

18. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001; 86:3562–7.

19. van Geest RJ, Sasim IV, Koppeschaar HP, et al. aberrations pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008; 158:229–37.

20. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326:581–8.

21. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol. 2008; 126:994–5.

22. Nugent RA, Rootman J, Robertson WD, et al. Acute orbital pseudotumors: classification and CT features. AJR Am J Roentgenol. 1981; 137:957–62.

23. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Measuring eye movement in Graves' ophthalmopathy. Ophthalmology. 1994; 101:1341–6.

24. Prummel MF, Bakker A, Wiersinga WM, et al. Multicenter study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European group on Graves' orbitopathy experience. Eur J Endocrinol. 2003; 148:491–5.

25. Char DH, Miller T. Orbital pseudotumor, Fine-needle aspiration biopsy and response to therapy. Ophthalmology. 1993; 100:1702–10.

26. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev. 1982; 65:133–55.

27. Fan PT, Yu DT, Clements PJ, et al. Effect of corticosteroids on the human immune response: Comparison of one and three daily 1-gm intravenous pulses of methylprednisolone. J Lab Clin Med. 1978; 91:625–34.

28. Melby JC. Clinical pharmacology of systemic corticosteroids. Annu Rev Pharmacol Toxicol. 1977; 17:511–27.

29. Kim J-Y, Ahn M. Side effects of intravenous methylprednisolone pulse therapy in eye diseases. J Korean Ophthalmol Soc. 2008; 49:14–8.